Volitionrx limited announces publication of significant nu.q® capture mass spectrometry paper

Austin, texas, march 31, 2021 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the publication in scientific reports of a paper entitled " a novel proteomics approach to epigenetic profiling of circulating nucleosomes ". dr. marielle herzog, lead author of the paper and volition's research and development director, commented, "our novel method detects and quantifies histone modifications present in the circulating nucleosomes in the blood of cancer patients.
VNRX Ratings Summary
VNRX Quant Ranking